The PaceNew therapies / indications available since the last 12 months 
Vabysmo
BY: Winnie TangMar 22, 2023

Vabysmo

(faricimab) Roche

 

Composition1,2:

  • Injection: 120 mg/mL solution in a single-dose vial. 

 

Indications1,2:

Vabysmo is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with:

  • Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
  • Diabetic Macular Edema (DME)

 

Reference:

1. Drug Office. Department of Health, HKSAR. https://www.drugoffice.gov.hk/eps/drug/productDetail/en/pharmaceutical_trade/141191 (accessed on 27 Jan 2023)  2. Vabysmo (faricimab). US Prescribing Information 2022

You May Be Interested In
Ajovy®
BY: Jasper ChanMar 18, 2022
ELREXFIO™
BY: Eura SoJun 20, 2024
MOUNJARO®
BY: Eura SoJun 20, 2024
Omacor
BY: Olive TseDec 20, 2021